# AOD-9604

Canonical source: https://retacompare.com/encyclopedia/aod-9604

Originally developed as a lipolytic / anti-obesity agent; later studied for cartilage repair via influence on chondrocyte proliferation.

Reference facts

Also known asAnti-Obesity Drug 9604, hGH 177-191CategoryHealing & Tissue RepairMechanism of actionOriginally developed as a lipolytic / anti-obesity agent; later studied for cartilage repair via influence on chondrocyte proliferation.Targetsβ3-adrenergic receptor (proposed), Chondrocyte signalingIndications under research or approvedFailed Phase 2 obesity (2007); research in osteoarthritisRegulatory status (reference entry)Not FDA-approved (cosmetic GRAS in some jurisdictions)Half-life~38 minutesSequenceYLRIVQCRSVEGSCGFSequence notes16-residue C-terminal fragment of human growth hormone (177-191) with an added N-terminal tyrosine; intramolecular disulfide between Cys7-Cys13.Molecular weight (Da)1815Originator / sponsorOriginally Metabolic Pharmaceuticals (Australia)First reported2002
    Primary References

Heffernan et al., Endocrinology 2001 (hGH fragment lipolysis)


    Explore research articles about AOD-9604


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Heffernan et al., Endocrinology 2001 (hGH fragment lipolysis): https://pubmed.ncbi.nlm.nih.gov/11459784/